Identification of tumour-associated T-cell epitopes for vaccine development

Nature Reviews Cancer

Volumn 2, Issue 7, 2002, Pages 514-520

  Stevanovic, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EPITOPE; GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; MUCIN 1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RAS PROTEIN; TUMOR ANTIGEN; ANTIGEN;

BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MICROARRAY; GASTROINTESTINAL CARCINOMA; GLIOMA; HELPER CELL; HUMAN; IMMUNOGENICITY; KAPOSI SARCOMA; MELANOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; REVIEW; T LYMPHOCYTE; THYROID MEDULLARY CARCINOMA; UTERINE CERVIX CARCINOMA; VACCINATION; ALLELE; BIOLOGICAL MODEL; CHEMISTRY;

ALLELES; ANTIGENS; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; MODELS, BIOLOGICAL; T-LYMPHOCYTES;

EID: 0036631492     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Renkvist, N., Castelli, C., Robbins, P. F. & Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50, 3-15 (2001).
2. Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
3. Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
4. Lee, K. H. et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292-6300 (1999).
5. Panelli, M. C. et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART1 and GP100. J. Immunother. 23, 487-498 (2000).
6. Bodey, B., Bodey, B. Jr, Siegel, S. E. & Kaiser, H. E. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20, 2665-2676 (2000).
7. Ohnmacht, G. A. et al. Short-term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167, 1809-1820 (2001).
8. Tait, B. D. HLA class I expression on human cancer cells. Implications for effective immunotherapy. Hum. Immunol. 61, 158-165 (2000).
9. Seliger B. et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61, 8647-8650 (2001).
10. Rammensee, H.-G., Bachmann, J., Emmerich, N., Bachor, O. A. & Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219 (1999).
11. Vonderheide, R. H. et al. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. 7, 3343-3348 (2001). An actual example of reverse immunology, using a ubiquitous tumour antigen, telomerase. Epitope identification was achieved after induction of peptide-specific T cells.
12. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60, 4845-4849 (2000).
13. Mashino, K. et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br. J. Cancer 85, 713-720 (2001).
14. Gillespie, A. M. et al. MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br. J. Cancer 78, 816-821 (1998).
15. Russo, V. et al. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int. J. Cancer 64, 216-221 (1995).
16. van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991).
17. Traversari, C. et al. A nonapeptide encoded by human gene MAGE1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176, 1453-1457 (1992).
18. Smith, E. S. et al. Lethality-based selection of recombinant genes in mammalian cells: application to identifying tumor antigens. Nature Med. 7, 967-972 (2001). A new generation of expression libraries that comprises enrichment steps.
19. Cox, A. L. et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719 (1994).
20. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G. & Rammensee, H.-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296 (1991).
21. Rötzschke, O. et al. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21, 2891-2894 (1991).
22. Stevanovic, S. & Rammensee, H.-G. Identification of T-cell epitopes using allele-specific ligand motifs. Behring. Inst. Mitt. 95, 7-13 (1994).
23. Celis, E. et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl Acad. Sci. USA 91, 2105-2109 (1994).
24. Parker K. C., Bednarek, M. A. & Coligan, J. E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175 (1994).
25. Nussbaum, A. K. et al. PapRoC: a predicition algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53, 87-94 (2001).
26. Kesmir, C. et al. 〈http://www.cbs.dtu. dk/services/NetChop/〉.
27. Schirle, M., Weinschenk, T. & Stevanovic, S. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J. Immunol. Methods 257, 1-16 (2001).
28. Kessler, J. H. et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193, 73-88 (2001). Use of proteasomal digestion for the definition of HLA-presented peptides from tumour antigens.
29. Pascolo, S. et al. A MAGE-A1 HLA-A*0201 epitope identified by mass spectrometry. Cancer Res. 61, 4072-4077 (2001). Identification of a tumour-specific class I epitope by mass spectrometry without the use of pre-existing T cells.
30. Brossart, P. et al. Identification of HLA-A2 restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93, 4309-4317 (1999).
31. Schirle, M. et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30, 2216-2225 (2000).
32. Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92, 11810-11813 (1995).
33. Czerwenka, K. F. et al. Comparative analysis of two-dimensional protein patterns in malignant and normal human breast tissue. Cancer Detect. Prev. 25, 268-279 (2001).
34. Meehan, K. L., Holland, J. W. & Dawkins, H. J. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50, 54-63 (2002).
35. Emmert-Buck, M. R. et al. An approach to proteomic analysis of human tumors. Mol. Carcinog. 27, 158-165 (2000).
36. Mathiassen, S., Lauemöller, S. L., Ruhwald, M., Claesson, M. H. & Buus, S. Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur. J. Immunol. 31, 1239-1246 (2001). Candidate antigens from gene-expression profiling were used for epitope prediction, leading to protective T-cell epitopes in a mouse model.
37. Boer, J. M. et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 11, 1861-1870 (2001).
38. Klade C. S. et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1, 890-898 (2001).
39. van Driel, W. J. et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a Phase I-II trial. Eur. J. Cancer 35, 946-952 (1999).
40. Slingluff, C. L. Jr et al. Phase I trial of a melanoma vaccine with GP100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7, 3012-3024 (2001).
41. Brossart, P. et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96, 3102-3108 (2000).
42. Kobayashi, H., Song, Y., Hoon, D. S., Appella, E. & Celis, E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 61, 4773-4778 (2001). A recent example of how to identify tumour-specific HLA class-II-presented epitopes.
43. + cytolytic T lymphocytes. Cancer Res. 60, 6272-6275 (2000).
44. Kobayashi, H., Lu, J. & Celis, E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the GP100 melanoma tumor antigen. Cancer Res. 61, 7577-7584 (2001).
45. + T cells. Eur. J. Immunol. 31, 1910-1916 (2001).
46. H1 helper peptide elicits protective CTL immunity. Eur. J. Immunol. 31, 1780-1789 (2001).
47. Marks, M. S. et al. A lysosomal targeting signal in the cytoplasmic tail of the β-chain directs HLA-DM to MHC class II compartments. J. Cell Biol. 131, 351-369 (1995).
48. Sanderson, S., Frauwirth, K. & Shastri, N. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl Acad. Sci. USA 92, 7217-7221 (1995).
49. Malcherek, G. et al. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur. J. Immunol. 28, 1524-1533 (1998).
50. + T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J. Virol. 75, 10421-10430 (2001).
51. van der Bruggen, P. et al. A peptide encoded by human gene MAGE3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Eur. J. Immunol. 24, 3038-3043 (1994).
52. Jäger, E. et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-270 (1998).
53. Wölfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
54. Robbins, P. F. et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185-1192 (1996).
55. Mandruzzato, S., Stroobant, V., Demotte, N. & van der Bruggen, P. A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules. J. Immunol. 164, 4130-4134 (2000).
56. Ressing, M. E. et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154, 5934-5943 (1995).
57. Brichard, V. G. et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol. 26, 224-230 (1996).
58. Skipper, J. C. et al. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from PMEL17/GP100. J. Immunol. 157, 5027-5033 (1996).
59. Salgaller, M. L. et al. Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol. 18, 109-119 (1998).
60. Fisk, B., Blevins, T. L., Wharton, J. T. & Ioannides, C. G. Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181, 2109-2117 (1995).
61. Kawashima, I. et al. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 59, 431-435 (1999).
62. Scheibenbogen, C. et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23, 275-281 (2000).
63. Hunger, R. E. et al. Successful induction of immune responses against mutant RAS in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol. 10, 161-167 (2001).
64. + hematopoietic progenitor cells. Int. J. Cancer 86, 385-392 (2000).
65. Yu, J. S. et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842-847 (2001).
66. Gjertsen, M. K. et al. Intradermal RAS peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 92, 441-450 (2001).
67. + melanoma patients with MAGE3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7, S895-S901 (2001).
68. Schott, M. et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. 86, 4965-4969 (2001).
69. + cancers. Proc. Natl Acad. Sci. USA 97, 12198-12203 (2000).
70. Rosenberg, S. A. et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163, 1690-1695 (1999).
71. Murphy, G. P. et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38, 73-78 (1999).
72. Sadanaga, N. et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7, 2277-2284 (2001).